Amphiprotech
Focus: Amphiprotech is an early-stage biotech founded in 2022, headquartered in Shanghai, focusing on specialized delivery platforms for eye drops, pain treatment, and aerosol delivery systems. The company remains pre-revenue with no disclosed market position or scale metrics.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Open Jobs
0
About Amphiprotech
AI assessmentNot HiringNo open roles listed right now. Follow Amphiprotech to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Amphiprotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
0/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2022
H-1B (2023): 4 approvals
Help build intelligence for Amphiprotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.